Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278080 (
physical dependence
)
1,658
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It is frequently hypothesized that drug-induced alterations in the density of beta-adrenergic receptors underlie tolerance to and
physical dependence
on agonists and antagonists at beta-adrenergic receptors. Two approaches to determining the effect of treatment with drugs on the density of beta-adrenergic receptors are described. In the first, the density of beta-adrenergic receptors was measured on leukocytes taken from human subjects during and after drug treatment. Treatment with the antagonist propranolol caused an increase in the density of beta-adrenergic receptors on leukocytes, whereas treatment with the agonists terbutaline and ephedrine, or pindolol, an antagonist with intrinsic sympathomimetic activity, caused a decrease in the density of beta-adrenergic receptors. In the second approach, the effect of agonists on the density of beta-adrenergic receptors on C6 glioma cells in culture was determined. Incubation with the full agonist isoproterenol decreased the density of both beta 1- and beta 2-adrenergic receptors. In contrast, incubation with pindolol or celiprolol, also an antagonist with intrinsic sympathomimetic activity, selectively decreased the density of beta 2-adrenergic receptors. Pindolol and celiprolol may be useful in situations in which selective stimulation of beta 2-adrenergic receptors and blockade of beta 1-adrenergic receptors is desirable.
Am J
Cardiol
1986 Apr 25
PMID:Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. 287 41